Wall Street analysts forecast that PRA Health Sciences Inc (NASDAQ:PRAH) will post $1.27 earnings per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for PRA Health Sciences’ earnings, with the highest EPS estimate coming in at $1.30 and the lowest estimate coming in at $1.26. PRA Health Sciences reported earnings of $1.10 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.5%. The business is expected to announce its next earnings results on Wednesday, February 20th.

On average, analysts expect that PRA Health Sciences will report full-year earnings of $4.24 per share for the current financial year, with EPS estimates ranging from $4.19 to $4.27. For the next financial year, analysts anticipate that the firm will report earnings of $4.94 per share, with EPS estimates ranging from $4.80 to $5.06. Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 31st. The medical research company reported $1.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.06. The company had revenue of $717.60 million during the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The firm’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.88 earnings per share.

PRAH has been the subject of several analyst reports. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 25th. UBS Group initiated coverage on shares of PRA Health Sciences in a report on Tuesday, October 9th. They issued a “neutral” rating for the company. Evercore ISI initiated coverage on shares of PRA Health Sciences in a report on Thursday, October 4th. They issued an “inline” rating and a $120.00 target price for the company. Robert W. Baird increased their target price on shares of PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Tuesday, September 11th. Finally, KeyCorp reiterated a “buy” rating and issued a $115.00 target price on shares of PRA Health Sciences in a report on Thursday, August 2nd. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $111.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of PRAH. Twin Tree Management LP purchased a new stake in PRA Health Sciences during the second quarter worth about $120,000. Price Capital Management Inc. purchased a new stake in PRA Health Sciences during the third quarter worth about $121,000. Mount Yale Investment Advisors LLC increased its holdings in PRA Health Sciences by 103.6% during the second quarter. Mount Yale Investment Advisors LLC now owns 1,704 shares of the medical research company’s stock worth $159,000 after buying an additional 867 shares during the last quarter. Parallel Advisors LLC increased its holdings in PRA Health Sciences by 930.9% during the third quarter. Parallel Advisors LLC now owns 1,804 shares of the medical research company’s stock worth $199,000 after buying an additional 1,629 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in PRA Health Sciences during the second quarter worth about $201,000. Institutional investors and hedge funds own 98.82% of the company’s stock.

Shares of PRAH stock traded down $0.86 on Tuesday, hitting $100.60. The stock had a trading volume of 512,257 shares, compared to its average volume of 504,753. The company has a market cap of $6.54 billion, a P/E ratio of 26.68, a P/E/G ratio of 1.46 and a beta of 0.73. The company has a debt-to-equity ratio of 1.22, a current ratio of 0.89 and a quick ratio of 0.89. PRA Health Sciences has a 12-month low of $78.99 and a 12-month high of $112.88.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: S&P 500 Index

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.